Regimens and molecular profile corresponding to Patient 51 were entered into the decision-support platform and the resultant matching scores were computed: regimens that failed received a matching score of 17% (tamoxifen—matched to the ER positive expression) or 0% (FAC, cisplatin, capecitabine—not matched to any of the molecular markers presented by the tumor), while the regimen that led to the 11-month partial response received a score of 42% (anastrozole + everolimus—matched to the ER positive expression and the PTEN copy loss). This evidence concerns the gene ESR1 and neoplasm.